How does Bristol-Myers Squibb (BMY) make money?

Bristol-Myers Squibb (BMY) generates revenue primarily from Eliquis, which accounted for 31% of total revenue in TTM through Q1 2026. The company reported $48.48B in revenue and converted 15% of it into net profit, equivalent to roughly $7.28B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Bristol-Myers Squibb (BMY)?

Bristol-Myers Squibb (BMY) reported a gross profit margin of 68.7% in TTM through Q1 2026, equivalent to $33.33B in gross profit on $48.48B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Bristol-Myers Squibb (BMY)?

Bristol-Myers Squibb (BMY) reported an operating profit margin of 25.7% in TTM through Q1 2026, equivalent to $12.45B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Bristol-Myers Squibb (BMY)?

Bristol-Myers Squibb (BMY) reported a net profit margin of 15% in TTM through Q1 2026, equivalent to $7.28B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Bristol-Myers Squibb (BMY) profitable?

Yes. Bristol-Myers Squibb (BMY) reported $7.28B in net income for TTM through Q1 2026, with a net profit margin of 15%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does Bristol-Myers Squibb (BMY) invest in research and development?

Bristol-Myers Squibb (BMY) invested $10.03B in research and development during TTM through Q1 2026, roughly 20.7% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Bristol-Myers Squibb (BMY) spend on capital expenditures?

Bristol-Myers Squibb (BMY) spent $1.40B on capital expenditures (CapEx) during TTM through Q1 2026, roughly 2.9% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Bristol-Myers Squibb (BMY) generate?

Bristol-Myers Squibb (BMY) generated $11.91B in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 24.6%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of Bristol-Myers Squibb (BMY)?

Bristol-Myers Squibb (BMY) had an effective tax rate of 24.2% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of Bristol-Myers Squibb (BMY)?

Bristol-Myers Squibb (BMY) reports revenue across 20 reportable product segments, led by Eliquis at 31% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

Where does Bristol-Myers Squibb (BMY) generate most of its revenue?

UNITED STATES is the largest geographic market for Bristol-Myers Squibb (BMY), accounting for 87.8% of revenue in the most recent annual filing. The complete regional split — including international markets and any Rest-of-World rollup — is shown in the revenue-by-geography table on this page.

How Bristol-Myers Squibb Makes Money: 2026 Visual Revenue Map

Bristol-Myers Squibb (BMY) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported April 30, 2026).

Bristol-Myers Squibb (BMY) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for Bristol-Myers Squibb (BMY) in TTM through Q1 2026.
Segment	Revenue (USD)	% of total
Eliquis	$15.01B	31%
Opdivo	$9.93B	20.5%
Orencia	$3.75B	7.7%
Yervoy	$2.93B	6%
Pomalyst/Imnovid	$2.59B	5.3%
Reblozyl	$2.40B	5%
Revlimid	$2.36B	4.9%
Other Growth	$2.10B	4.3%
Other segments	$7.41B	15.3%
Total	$48.48B	100%

Eliquis$15.01B
Opdivo$9.93B
Orencia$3.75B
Yervoy$2.93B
Pomalyst/Imnovid$2.59B
Reblozyl$2.40B
Revlimid$2.36B
Other Growth$2.10B
Other segments$7.41B
Total$48.48B

Bristol-Myers Squibb (BMY) Revenue by Geography — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.

Revenue contribution by geographic region for Bristol-Myers Squibb (BMY), TTM through Q1 2026
Region	Revenue (USD)	% of total
UNITED STATES	$33.19B	87.8%
Rest Of World	$3.48B	9.2%
Other Region	$1.13B	3%
Total	$37.80B	100%

UNITED STATES
Rest Of World
Other Region
Total

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, Bristol-Myers Squibb (BMY) reports revenue across 20 operating segments; the largest segment was Eliquis at 31%, followed by Opdivo (20.5%) and Orencia (7.7%). Separately, by end-market geography, UNITED STATES accounted for 87.8% of revenue, followed by Rest Of World (9.2%) and Other Region (3%).

Frequently asked questions

Data & methodology

Bristol-Myers Squibb (BMY) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation